Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SECOND SIGHT MEDICAL PRODUCTS INC | ex_132640.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 9, 2019
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|||||
|
(Exact Name of Registrant as Specified in Its Charter) |
|
California |
|||||
|
(State or Other Jurisdiction of Incorporation) |
| 333-198073 | 02-0692322 | |||
| (Commission File Number) | (IRS Employer Identification No.) |
| 12744 San Fernando Road, Suite 400 Sylmar, California 91342 |
||
| (Address of Principal Executive Offices) |
|
(818) 833-5000 |
|||||
|
(Registrant's Telephone Number, Including Area Code) |
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
ITEM 7.01. REGULATION FD DISCLOSURE
A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight") intends to use during a presentation at the Digital Medicine and Medtech Showcase 2019, on Wednesday, January 9, 2019 (the "Presentation Materials") is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No. Description
99.1 Second Sight Medical Products, Inc. Investor Presentation dated January 9, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 9, 2019
SECOND SIGHT MEDICAL PRODUCTS, INC.
| /s/ John T. Blake | ||
| By: John T. Blake | ||
| Chief Financial Officer |
-2-